<DOC>
	<DOC>NCT00769899</DOC>
	<brief_summary>This is a Phase I randomized double-blind, placebo-controlled, single centre study to assess the safety, tolerability and pharmacokinetics of AZD7325 following single ascending dose administration to healthy male Japanese volunteers.</brief_summary>
	<brief_title>AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI) : 18 to 27 kg/m 2 Clinically relevant disease and/or abnormalities (past or present) Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator Use of any medication or herbal preparation within 14 days of Study day 1 through the Followup Visit other than paracetamol (up to 3 g/day) Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to the first study day or inability to refrain from smoking during the study confinement period</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>AZD7325</keyword>
	<keyword>Japanese Healthy Volunteers</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Single Ascending Dose</keyword>
</DOC>